Iqvia downgraded to Neutral from Buy at BTIG

BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization commentary from a large healthcare conference in January was more cautious than it had expected. BTIG worries that Iqvia may continue to face headwinds through the first half of 2025 and possibly into 2026. Challenges are coming from an ongoing slowdown in clinical trial activity by bio-pharma due to the Inflation Reduction Act, changes in Medicare reimbursement, and continued tough compare from the COVID era due to a pull-forward of research into 2020 and 2021, the analyst tells investors in a research note.